Swissmedic
REGULATORY UPDATE
CIRS study on authorisation times for human medicinal products with new active substances confirms Swissmedic’s competitiveness internationally
Published: 7/6/2026Detected: 7/6/2026
Summary preview
Confirms Swissmedic’s competitiveness internationally by reporting findings from a CIRS study on authorisation timelines for human medicinal products containing new active substances.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountmanufacturing
quality
clinical
safety
labeling
#Swissmedic
#CIRS study
#authorisation times
#new active substance
#human medicinal products
Official Source Document Source Verified
Access the original document directly from SWISSMEDIC.
More from Swissmedic
- Extended deadline for publishing officially mandated information materials on the electronic publication platform11/12/2026
- Designer drugs: FDHA brings further psychoactive substances under control11/10/2026
- NAD+ supplements: When lifestyle products have criminal consequences11/9/2026
- Publication eCTD v4.0 Implementation Guide Package v2.011/9/2026
- Save the Date: Clinical Trials Symposium 202711/4/2026